National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Enzalutamide (Xtandi®) is indicated for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).


NCPE Assessment Process Complete
Rapid review commissioned 18/12/2018
Rapid review completed 06/02/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with ADT compared with the current standard of care


The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.